Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy

Figures & data

Table 1 Baseline characteristics

	Group A (1–4 DA) n=23	Group B (4–9 DA) n=15	Group C (>9 DA) n=8	Total n=46
Age, years (mean)	76.4	79.3	77.8	77.2
Sex (F/M) Artery hypertension	16/6 17 (74%)	12/6 10 (67%)	4/2 6 (75%)	32/14 33 (72%)
Diabetes	3 (13%)	2 (13%)	2 (25%)	7 (15%)
Anticoagulant medication	11 (48%)	9 (60%)	4 (50%)	24 (52%)

Abbreviations: DA, disc area; F, female; M, male; n, number of eyes.

Table 2 Changes in visual acuity at 12-month follow-up

	Improvement	Unchanged	Worsening	Baseline mean BCVA logMAR (95% CI)	12-month mean BCVA logMAR (95% CI)	P-value
	(≥1 ETDRS line)		(≥1 ETDRS line)
Group A (n=23)	13 (57%)	2 (9%)	8 (35%)	0.67 (0.53–0.80)	0.60 (0.43–0.76)	0.11
Group B (n=15)	8 (53%)	1 (7%)	6 (40%)	0.86 (0.68–1.05)	0.79 (0.54–1.03)	0.26
Group C (n=8)	3 (38%)	1 (13%)	4 (50%)	1.12 (0.74–1.51)	1.14 (0.85–1.43)	0.52
Total (n=46)	24 (52%)	4 (9%)	18 (39%)	0.81 (0.70–0.92)	0.75 (0.62–0.88)	0.15

Note: Data were compared using the Wilcoxon signed-rank test.

Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; logMAR, logarithm of the minimum angle of resolution; CI, confidence interval.